135734-96-2

Basic information

• Product Name: (E)-2-(4-hydroxy-3-Methoxybenzylidene)cyclopentanone
• Synonyms: (E)-2-(4-hydroxy-3-Methoxybenzylidene)cyclopentanone
• CAS NO: 135734-96-2
• Molecular Formula: C₁₃H₁₄O₃
• Molecular Weight: 218.24846
• Mol File: 135734-96-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (E)-2-(4-hydroxy-3-Methoxybenzylidene)cyclopentanone(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-2-(4-hydroxy-3-Methoxybenzylidene)cyclopentanone(135734-96-2)
• EPA Substance Registry System: (E)-2-(4-hydroxy-3-Methoxybenzylidene)cyclopentanone(135734-96-2)

Safety Data

• Hazardous Substances Data: 135734-96-2(Hazardous Substances Data)

Usage

General Description

(E)-2-(4-hydroxy-3-Methoxybenzylidene)cyclopentanone, also known as HMC, is a chemical compound with the molecular formula C13H14O3. It is a yellow crystalline powder with a distinctive odor and is commonly used as a flavoring agent in the food industry. HMC has been found to exhibit antioxidant, anti-inflammatory, and anti-cancer properties, making it a potential candidate for use in pharmaceutical and nutraceutical products. Additionally, it has been studied for its potential use in the treatment of neurodegenerative diseases such as Alzheimer's. HMC is also being investigated for its antimicrobial and antifungal properties, and its potential use in the development of new drug therapies.

Upstream product

• 936-52-7 1-(N-morpholino)cyclopent-1-ene 
• 121-33-5 vanillin 
• 120-92-3 cyclopentanone 
• 13330-65-9 2,4-dimethoxyphenol 

Downstream Products

• 1393829-69-0 2-(4-hydroxy-3,5-dimethoxybenzylidene)-5-(4-hydroxy-3-methoxybenzylidene)cyclopentanone 

Relevant articles and documents

Synthesis, biological evaluation, QSAR and molecular dynamics simulation studies of potential fibroblast growth factor receptor 1 inhibitors for the treatment of gastric cancer

Accumulating evidence suggests that fibroblast growth factor receptor 1 (FGFR1) is an attractive target in gastric cancer therapy. Based on our previous discovery of two non-ATP competitive FGFR1 inhibitors, A114 and A117, we designed and screened a series of compounds with the framework of bisaryl-1,4-dien-3-one. Among them, D12 and D15 exhibited the most potent FGFR1 inhibitory activity, which was ATP-independent. Furthermore, a quantitative structure-activity relationship analysis of 41 analogs demonstrated that the specific structural substitutions alter their bioactivities. Molecular docking and dynamics simulation analysis indicated the hydrophobic interaction at the FGFR1-D12/D15 interaction was dominant. Evaluation for anti-gastric cancer efficacy of D12 and D15 indicated effective inhibition of cell proliferation, apoptosis induction and cell cycle arrest. Thus, these two FGFR1 inhibitors have therapeutic potential in the treatment of gastric cancer, and this study provides will contribute to the rational design of novel non-ATP competitive FGFR1 inhibitors.

2-METHYLENE-5-SUBSTITUTED-METHYLENECYCLOPENTANONE DERIVATIVES AND USE THEREOF

The invention relates to 2-methylene-5-substituted-methylenecyclopentanone derivatives of formula I, and the use thereof. The derivatives of formula I as active components are useful for preparing a medicine for the treatment and/or prevention of cancer diseases such as breast cancer, lung cancer, colon cancer, rectal cancer, stomach cancer, prostate cancer, bladder cancer, uterus cancer, pancreatic cancer and ovary cancer. The active compounds of the invention may be used as an anticancer drug alone or used in combination with one or more other antitumor drugs. A combined therapy can be carried out by administrating each therapeutic component concurrently, subsequently or separately.

Synthesis of CIS- and trans- 2-arylmethylcycloalkylamines: Potential dopaminergic agents

This paper reports the synthesis and the study of a few new diastereomeric arylmethylcycloalkylamines, tested as potential dopamine receptor active agents. New procedures for the stereospecific synthesis of the arylmethylcycloalkylamines were successfully experimented. All the considered compounds did not show any appreciable dopamine receptor activity.